Surgery – Means for introducing or removing material from body for... – Treating material introduced into or removed from body...
Reexamination Certificate
2001-11-05
2003-03-25
Kennedy, Sharon (Department: 3763)
Surgery
Means for introducing or removing material from body for...
Treating material introduced into or removed from body...
C128S898000
Reexamination Certificate
active
06537265
ABSTRACT:
BACKGROUND OF THE INVENTION
This is a Continuation-in-Part of U.S. application Ser. No. 09/877,605, filed Jun. 8, 2001, now abandoned.
This invention relates to delivery of a medical substance to a mammal and more particularly relates to nasal delivery of such a substance for absorption, reaction or other utilization.
Nasal administration of medical substances has had significant disadvantages. Dosages have been difficult to control due to excretory responses to administration, e.g. sneezing and mucosal excretion that removes or significantly reduces the substance from the nasal passages and sinuses. Another problem is that administered substances removed by an excretory response are often swallowed leading to nausea, stomach upset or other digestive disturbance. An even more serious problem is that if the excretory response is strong enough, the substance can be inhaled causing coughing or more serious pulmonary distress. An even further problem is that when a significant amount of the medical substance is removed by an excretory response, the material excreted is wasted material, thus increasing costs and inefficiencies associated with nasal administration.
BRIEF DESCRIPTION OF THE INVENTION
In accordance with the invention a method is therefore provided for nasal application of a medicinal substance which overcomes the above disadvantages. In particular, the method comprises applying the substance through the nose in a maximum amount that is insufficient to stimulate an excretory response that would clear a significant portion of the substance from nasal and sinus passages and within a time period of less than one hour, and repeating the application of the substance, through the nose in an amount that is insufficient to stimulate an excretory response that would clear a significant portion of the substance from nasal and sinus passages. The repeated application, at a minimum, is done a sufficient number of times to provide an effective total dose of the substance. The repeated application, in any case, is done at least once.
REFERENCES:
patent: 598286 (1898-02-01), Curran
patent: 4381773 (1983-05-01), Goodnow et al.
patent: 4886493 (1989-12-01), Yee
patent: 5116311 (1992-05-01), Lofstedt
patent: 5284132 (1994-02-01), Geier
patent: 5429600 (1995-07-01), Heinke
patent: 5713855 (1998-02-01), Shippert
patent: 6085753 (2000-07-01), Gonda et al.
Berstad, Aud Katrine Herland, et al. “Inactivated Meningococci and Pertussis Bacteria are Immunogenic and Act as Mucosal Adjuvants for a Nasal Inactivated Influenza”, Vaccine, 182000, pp. 1910-1919.
Childers, Noel K., et al. “Adjuvant activity of Monophosphoryl Lipid A for Nasal and Oral Immunization with Soluble of Liposome-Associated Antigen”, Infection and Immunity,2000, pp. 5509-5516.
Dupuy, Catherine, et al. “Nasal Immunization of Mice with Human Papillomavirus Type 16 (HPV-16) Virus-Like Particles or with HPV-16 L1 Gene Elicits Specific Cytotoxic T Lymphocytes in Vaginal Draining Lymph Nodes”, Journal of Virology, 1999, pp. 9063-9071.
Eyles, Jim E., et al. “Immunological Responses to Nasal Delivery of Free and Encapsulated Tetanus Toxoid: Studies on the Effect of Vehicle Volume”, International Journal of Pharmaceutics,189, 1999, pp. 75-79.
Gallichan, W. Scott, et al. “Long-Term Immunity and Protection Against Herpes Simplex Virus Type 2 in the Murine Female Genital Tract after Mucosal but not Systemic Immunization”,Journal of Infectious Diseases, 177, 1998, pp. 1155-1161.
Klavinskis, Linda S., et al. “Intranasal Immunization with Plasmid DNA-Lipid Complexes Elicits Mucosal Immunity in the Female Genital and Rectal Tracts”, Journal of Immunology,1999, pp. 254-262.
Lundholm, Peter, et al. “Induction of Mucosal IgA by a Novel Jet Delivery Technique for HIV-1 DNA”, Vaccine, 17, 1999, pp. 2036-2042.
McCluskie, Michael J., et al. “Cutting Edge: CpG DNA is a Potent Enhancer of Systemic and Muscosal Immune Responses Against Hepatitis B Surface Antigen with Intranasal Administration to Mice”, Journal of Immunology, 1998, pp. 4463-4466.
Pickett, Thames E., et al. “In Vivo Characterization of the Murine Intranasal Model for Assessing the Immunogenicity of AttenuatedSalmonella entericaSerovar Typhi Strains as Live Mucosal Vaccines and as Live Vectors”, Infection and Immunity, vol. 68, No. 1, 2000, pp. 205-213.
Saunders, Nancy B., et al. “Immunogenicity of Intranasally Administered Meningococcal Native Outer Membrane Vesicles in Mice”, Infection and Immunity, vol. 67, No. 1, 1999, pp. 113-119.
Shen, Xuzhuang, et al. “Group B Streptococcus Capsular Polysaccharide-Cholera Toxin B Subunit Conjugate Vaccines Prepared by Different Methods for Intranasal Immunization”, Infection and Immunity, vol. 69, No. 1, 2001, pp. 297-306.
Shen, Xuzhuang, et al. “Systemic and Mucosal Immune Responses in Mice after Mucosal Immunization with Group B Streptococcus Type III Capsular Polysaccharide-Cholera Toxin B Subunit Conjugate Vaccine”, Infection and Immunity, vol. 68, No. 10, 2000, pp. 5749-5755.
Trolle, Sylvine, et al. “Intranasal Immunization with Protein-Linked Phosphorycholine Protects Mice Against a Lethal Intranasal Challenge withStreptococcus pneumoniae”, Vaccine, 18,2000, pp. 2991-2998.
Bakaletz Lauren O.
Novotny Laura Anne
Thanavala Yasmin
Visweswaraiah Anju
Dunn Michael L.
Health Research , Inc.
Kennedy Sharon
LandOfFree
Method for nasal application of a medicinal substance does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for nasal application of a medicinal substance, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for nasal application of a medicinal substance will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3085088